Wolters Kluwer to acquire AI-powered clinical decision support platform AgileMD
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Wolters Kluwer (WTKWY) has signed an agreement to acquire AI-powered clinical decision support provider AgileMD for up to $100 million. The price includes $40 million upfront, with the balance deferred and contingent on performance targets. Wolters Kluwer expects closing in the first quarter of 2027 or sooner, subject to customary closing conditions and governmental approvals.
AgileMD is expected to reach $7 million in annual recurring revenue by year-end 2026; all 23 employees will join Wolters Kluwer Health. Wolters Kluwer expects the acquisition to earn a return on invested capital at or above its 8% after-tax weighted average cost of capital within 3–5 years, with an immaterial impact on adjusted earnings. The company plans to use AgileMD to expand UpToDate into embedded workflows and local guidelines. UpToDate Expert AI has been adopted by more than 2,700 U.S. hospitals and health systems since its September 2025 introduction.
Positive
- Minor pointSigned AgileMD acquisition agreement adds AI-powered clinical decision support, subject to closing.
- Minor point. Forward-looking: it has not happened yet and may not happen.AgileMD is expected to reach $7 million annual recurring revenue by year-end 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Acquisition return on invested capital is expected to reach or exceed 8% within 3–5 years.
- Minor point. Forward-looking: it has not happened yet and may not happen.Wolters Kluwer plans to expand UpToDate into embedded workflows and local guidelines through AgileMD.
- Minor pointUpToDate Expert AI adoption exceeds 2,700 U.S. hospitals and health systems, representing over 95% of U.S.-based Enterprise Edition customers.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Acquisition consideration is up to $100 million: $40 million upfront, with the balance deferred and performance-contingent.
- Minor pointClosing remains subject to governmental approvals, with completion expected in the first quarter of 2027 or sooner.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Alphen aan den Rijn, NL – November 13, 2026 – Wolters Kluwer Health has signed an agreement to acquire AgileMD, a healthcare technology company, for up to
AgileMD provides AI-powered clinical decision support for health care professionals, offering them interactive clinical pathways and predictive analytics to enhance consistency in care and help them to reduce mortality rates. The company’s Pathways product operationalizes local guidelines in the EHR workflow for consistency in care and outcomes measurement. Its eCART solution is a real-time AI-powered clinical surveillance engine that is FDA1-cleared and designed to help reduce mortality rates.
“Combined with UpToDate Expert AI and our partnerships, AgileMD will serve as a vital enabler for true UpToDate ubiquity in healthcare – facilitating UpToDate’s expansion into embedded workflows, local guidelines, and new digital health applications,” said Yaw Fellin, Senior Vice President, Wolters Kluwer Clinical Solutions. “With AgileMD, we are well positioned to help healthcare systems provide better patient care and extract more value from their tech investments.”
Borna Safabakhsh, Co-Founder and CEO at AgileMD, commented, “We are excited to join Wolters Kluwer Health. Coupled with UpToDate, AgileMD can more fully deliver its transformative impact in critical decision support workflows. Leveraging UpToDate’s foundational capabilities, AgileMD will accelerate and streamline the development and maintenance of more advanced clinical pathways for complex clinical decision-making support.”
Since its introduction in September 2025, UpToDate Expert AI has been adopted by more than 2,700 U.S. hospitals and health systems, representing more than
Additional information and financial terms
AgileMD, based in San Francisco, was founded in 2011 and is currently led by co-founders Borna Safabakhsh and Dana Edelson, M.D., Chief Medical Officer. All 23 employees will be joining Wolters Kluwer Health. AgileMD has seen strong growth and is expected to reach annual recurring revenues (ARR) of
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2025 annual revenues of
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
MEDIA AND IR CONTACTS
André Rebelo
Director, External Communications, Health
andre.rebelo@wolterskluwer.com
+1 (781) 392-2411
Leon Willems
Corporate Media Relations & Press Office Lead
leon.willems@wolterskluwer.com
+31 (0)6 15 20 87 99
Meg Geldens
Vice President, Investor Relations
ir@wolterskluwer.com
Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by global pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries
1 U.S. Food and Drug Administration.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much will Wolters Kluwer pay to acquire AgileMD?
The purchase price is up to $100 million, including a $40 million upfront payment. The balance is deferred consideration contingent on reaching certain performance targets.
When is Wolters Kluwer expected to complete the AgileMD acquisition?
Wolters Kluwer expects the acquisition to close in the first quarter of 2027 or sooner. Completion is subject to customary closing conditions and governmental approvals.